Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 85
Filter
1.
J Vet Cardiol ; 48: 7-18, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37276765

ABSTRACT

BACKGROUND: Echocardiographic indices of the inferior vena cava have been associated with elevated right atrial pressures in humans. HYPOTHESIS/OBJECTIVES: Describe caudal vena caval (CVC) sonographic dimensions in healthy cats compared to cats with cardiogenic cavitary effusion (CCE), cardiogenic pulmonary edema (CPE), or non-cardiac causes of cavitary effusion (NCE). ANIMALS: 30 healthy control cats and 52 client-owned cats with CCE, CPE, or NCE examined at two university hospitals. METHODS: Sagittal 2-dimensional (2D) and M-mode CVC dimensions were acquired from the subxiphoid view. Caudal vena cava collapsibility index (CVC-CI) was calculated. Variables were compared between study groups using Kruskal-Wallis and Dunn's Bonferroni testing. Receiver operating characteristic curves were used to assess sensitivity and specificity for diagnostic categories. RESULTS: Healthy cats had sagittal 2D and M-mode (median, interquartile range) CVC maximal dimensions of 2.4 mm (1.3-4.0) and 3.4 mm (1.5-4.9) and CVC-CI of 52% (45.2-61.8) and 55% (47.8-61.3), respectively. The CVC maximal dimensions in healthy controls were smaller than in cats with cavitary effusions or pulmonary edema (all P<0.05). CVC-CI was different between CCE and NCE (P<0.0001) with cutoffs of CVC-CI ≤38% (2D) or ≤29% (M-mode) being 90.5% and 85.7% sensitive, and 94.4% and 100% specific for diagnosis of CCE, respectively. CONCLUSIONS AND CLINICAL IMPORTANCE: Caudal vena cava measurements are larger in cats with cavitary effusions and cats with CPE than healthy cats. In cats with cavitary effusion, decreased CVC-CI, ≤38% (2D) or ≤29% (M-mode), was helpful in distinguishing between cardiogenic and noncardiogenic etiology.


Subject(s)
Cat Diseases , Heart Failure , Pulmonary Edema , Humans , Cats , Animals , Pulmonary Edema/veterinary , Vena Cava, Inferior/diagnostic imaging , Echocardiography/veterinary , Heart Failure/diagnostic imaging , Heart Failure/veterinary , Heart Failure/complications , Ultrasonography/veterinary , Cat Diseases/diagnostic imaging
2.
J Vet Cardiol ; 40: 99-109, 2022 Apr.
Article in English | MEDLINE | ID: mdl-33741312

ABSTRACT

INTRODUCTION: Dilated cardiomyopathy (DCM) in dogs has been associated with feeding of grain-free (GF), legume-rich diets. Some dogs with presumed diet-associated DCM have shown improved myocardial function and clinical outcomes following a change in diet and standard medical therapy. HYPOTHESIS: Prior GF (pGF) diet influences reverse cardiac remodeling and clinical outcomes in dogs with DCM and congestive heart failure (CHF). ANIMALS AND METHODS: A retrospective study was performed with 67 dogs with DCM and CHF for which diet history was known. Dogs were grouped by diet into pGF and grain-inclusive (GI) groups. Dogs in the pGF group were included if diet change was a component of therapy. Survival was analyzed using Kaplan-Meier curves and the Cox proportional-hazards model. RESULTS: The median survival time was 344 days for pGF dogs vs. 253 days for GI dogs (P = 0.074). Statistically significant differences in median survival were identified when the analysis was limited to dogs surviving longer than one week (P = 0.033). Prior GF dogs had a significantly worse outcome the longer a GF diet was fed prior to diagnosis (P = 0.004) or if they were diagnosed at a younger age (P = 0.017). Prior GF dogs showed significantly greater improvement in normalized left ventricular internal diastolic diameter (P = 0.038) and E-point septal separation (P = 0.031) measurements and significant decreases in their furosemide (P = 0.009) and pimobendan (P < 0.005) dosages over time compared to GI dogs. CONCLUSIONS: Prior GF dogs that survived at least one week after diagnosis of DCM, treatment of CHF, and diet change had better clinical outcomes and showed reverse ventricular remodeling compared to GI dogs.


Subject(s)
Cardiomyopathy, Dilated , Dog Diseases , Heart Failure , Animals , Dogs , Cardiomyopathy, Dilated/diagnosis , Cardiomyopathy, Dilated/veterinary , Diet/veterinary , Dog Diseases/diagnosis , Echocardiography/veterinary , Edible Grain , Heart Failure/complications , Heart Failure/therapy , Heart Failure/veterinary , Retrospective Studies
3.
J Vet Cardiol ; 40: 15-50, 2022 Apr.
Article in English | MEDLINE | ID: mdl-34750089

ABSTRACT

Dilated cardiomyopathy (DCM) is a frequent cause of cardiac disability, congestive heart failure (CHF), and arrhythmic death in dogs. The etiology of DCM is usually idiopathic/genetic, but some causes of a DCM phenotype are reversible. The disease is classified into preclinical (occult) and clinical (overt) stages; the latter stems from heart failure with reduced ejection fraction. DCM is further characterized by clinical, electrocardiographic, circulating biomarker, and imaging abnormalities. The diagnosis of clinical DCM with CHF is straightforward; however, identification of the preclinical stage can be challenging. Echocardiography is central to the diagnosis of both stages and characterized by left ventricular (LV) systolic dysfunction with progressive chamber dilation and variable enlargements of the left atrium and right-sided chambers. Left ventricular dilation is defined by increased LV end-diastolic volumes, areas, and internal dimensions normalized to body size or indexed to the aorta. Systolic dysfunction is characterized by decreased LV ejection fraction, increased end-systolic volume, and reduced shortening across minor and longitudinal LV axes. Dyssynchrony can confound the interpretation of linear indices of systolic function. A comprehensive echocardiogram in DCM includes two-dimensional and M-mode studies, spectral and tissue Doppler imaging, and potentially three-dimensional echocardiography and myocardial strain imaging. Echocardiographic findings should be interpreted within the context of identifiable risks and comorbidities, physical diagnosis, complementary diagnostic testing, and limitations of current reference intervals. Ambiguous examinations should be repeated. Specific echocardiographic criteria for the diagnosis of DCM are proposed to encourage discussion and additional outcome and breed-specific echocardiographic studies of canine DCM.


Subject(s)
Cardiomyopathy, Dilated , Dog Diseases , Heart Failure , Ventricular Dysfunction, Left , Animals , Cardiomyopathy, Dilated/diagnostic imaging , Cardiomyopathy, Dilated/veterinary , Dog Diseases/diagnostic imaging , Dogs , Echocardiography/veterinary , Heart Failure/etiology , Heart Failure/veterinary , Stroke Volume , Ventricular Dysfunction, Left/diagnostic imaging , Ventricular Dysfunction, Left/veterinary , Ventricular Function, Left
4.
J Vet Cardiol ; 34: 29-36, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33548736

ABSTRACT

INTRODUCTION/OBJECTIVES: Pulmonary stenosis (PS) is a common congenital defect in the dog. Severe valvar PS can be treated with balloon valvuloplasty (BV) to reduce obstruction severity and improve clinical signs. Repeat BV is often unnecessary, as restenosis is uncommon. Repeated pulmonary BV in people is generally successful and safe, but outcomes in dogs with recurrent or persistent stenosis have not been reported. The objectives of this study were to retrospectively evaluate outcomes of repeat BV in dogs. ANIMALS, MATERIALS, AND METHODS: Medical records and stored echocardiographic images were reviewed from dogs that received repeat BV for pulmonary valvar restenosis or persistent stenosis. Echocardiographic variables included maximum systolic ejection velocity (PVmax), velocity-derived maximal pressure gradient (PGmax) and velocity time integral (VTI) across the pulmonary valve, and ratios of pulmonic to aortic maximum velocity (PVmax/AVmax) and VTI (VTIPV/VTIAV). RESULTS: Twenty-three dogs were included; one underwent three BV procedures. The median time between BV procedures was 18.3 months (interquartile range, 6.3-43.6). One dog died during repeat BV, but no others experienced adverse effects. Reductions in PVmax, PGmax, and VTIPV after initial and repeat BV were 1.85 m/s, 76.2 mmHg, and 44.7 cm and 1.33 m/s, 55.6 mmHg, and 30.2 cm, respectively (all p < 0.01). Differences between pre-BV and post-BV PVmax, PGmax, VTIPV, PVmax/AVmax, and VTIPV/VTIAV were not different comparing initial to repeat BV (all p > 0.10). CONCLUSIONS: Repeat BV for recurrent or persistent PS is well tolerated and effective in a majority of dogs.


Subject(s)
Balloon Valvuloplasty , Dog Diseases , Pulmonary Valve Stenosis , Animals , Balloon Valvuloplasty/veterinary , Dog Diseases/therapy , Dogs , Echocardiography/veterinary , Pulmonary Valve Stenosis/therapy , Pulmonary Valve Stenosis/veterinary , Retrospective Studies
5.
J Vet Cardiol ; 23: 112-121, 2019 Jun.
Article in English | MEDLINE | ID: mdl-31174721

ABSTRACT

A 2-year-old intact female mixed breed dog was presented for ascites. Echocardiography demonstrated severe obstruction at the level of the caudal right atrium. Initially, a variant of cor triatriatum dexter was diagnosed, and balloon catheter dilation was performed. However, ascites recurred within a week. Further imaging revealed an obstruction at the entrance of the caudal vena cava into the right atrium rather than a dividing membrane in the right atrium. The diagnosis was revised to suprahepatic obstruction of the caudal vena cava because of remnant Eustachian valve tissue. Deployment of a balloon-expandable biliary stent was performed relieving the obstruction. Fifteen months after stent deployment, the patient is doing well without reaccumulation of ascitic fluid.


Subject(s)
Dog Diseases/therapy , Heart Defects, Congenital/veterinary , Stents/veterinary , Animals , Ascites/veterinary , Cineangiography/veterinary , Cor Triatriatum/therapy , Dog Diseases/congenital , Dog Diseases/diagnostic imaging , Dogs , Echocardiography/veterinary , Female , Heart Atria/abnormalities , Heart Defects, Congenital/therapy , Vena Cava, Inferior/abnormalities
6.
J Vet Cardiol ; 20(6): 399-404, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30526955

ABSTRACT

An 8-month-old Hanoverian gelding was presented with a history of cardiac murmurs that were not apparent as a foal nor reported at the time of castration. Major echocardiographic findings included mitral valvular thickening, functional stenosis, and mitral regurgitation of sufficient severity to cause diastolic and systolic cardiac murmurs, left-sided volume overload, and pulmonary hypertension. Due to the hemodynamic severity of the lesion and poor prognosis for future performance and longevity, euthanasia was elected. On gross postmortem examination, there was focal fibrous epicarditis affecting the heart base, and the left atrium was moderately dilated. The mitral valve surface was irregular and contained several nodules along the atrial face of the cusp. Histologically, this lesion was diagnosed as a vascular hamartoma, which is rarely reported in veterinary species and has not been described in heart valves. This benign proliferative lesion, and concurrent valvular dysfunction, was associated with an unusual manifestation of clinically evident disease and should be differentiated from common incidental valvular lesions such as hematocysts.


Subject(s)
Hamartoma/veterinary , Heart Murmurs/veterinary , Heart Valve Diseases/veterinary , Horse Diseases/diagnostic imaging , Mitral Valve , Animals , Diagnosis, Differential , Echocardiography/veterinary , Euthanasia, Animal , Hamartoma/diagnostic imaging , Heart Murmurs/diagnostic imaging , Heart Valve Diseases/diagnostic imaging , Horses , Male
7.
J Vet Cardiol ; 20(5): 330-342, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30143416

ABSTRACT

INTRODUCTION: Left ventricular (LV) and left atrial (LA) enlargement affect management and outcome of dogs with cardiac disease. Short-axis, two-dimensional echocardiographic (2DE) images, indexed to the aorta (Ao), are frequently used to identify cardiomegaly. Long-axis images offer complementary views of the left heart. ANIMALS: Eighty healthy dogs and 25 dogs with MMVD. METHODS: Healthy dogs were prospectively recruited to determine reference intervals (Clinical Laboratory Standards Institute methodology) for long-axis ratios. Measurement variability and repeatability were quantified by intraclass correlation coefficient and coefficient of variation. Mean long-axis ratios from dogs with MMVD were compared with healthy dogs (unpaired t-test). In addition, the proportion of MMVD dogs exceeding the 97.5 percentile by LV/Ao and a conventional, allometric method were compared (McNemar's test). RESULTS: Two-dimensional echocardiographic long-axis reference intervals were as follows: left ventricular to aortic dimension (LV/Ao) 1.8-2.5; left atrial to aortic dimension (LA/Ao) 1.8-2.4, and left atrial to left ventricular dimension (LA/LV) 0.9-1.1. Intraobserver and interobserver measurement agreement was good-to-excellent (intraclass correlation coefficients ≥0.84), and day-to-day variability was low (coefficient of variations <4%). Left ventricular to aortic dimension, LA/Ao, and LA/LV were significantly greater in canine MMVD compared with healthy dogs (p<0.001). The percentages of MMVD dogs demonstrating LV dilatation by LV/Ao and conventional method were 68% and 36%, respectively (p=0.043, 95% confidence interval for difference 7.9%, 56.1%). CONCLUSIONS: Simple 2DE long-axis ratios of LV/Ao, LA/Ao, and LA/LV are repeatable and demonstrate clinical utility for identifying LV and LA enlargement in dogs with MMVD.


Subject(s)
Dogs/anatomy & histology , Echocardiography/veterinary , Heart Atria/anatomy & histology , Heart Ventricles/anatomy & histology , Animals , Cohort Studies , Female , Heart Atria/diagnostic imaging , Heart Ventricles/diagnostic imaging , Male , Organ Size , Prospective Studies , Reference Values
8.
J Vet Intern Med ; 32(1): 64-71, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29224256

ABSTRACT

BACKGROUND: Right ventricular (RV) dysfunction independently predicts outcomes in human myxomatous mitral valve disease (MMVD). There is limited information regarding RV systolic function in dogs with MMVD. HYPOTHESIS: Right ventricular systolic function differs among stages of disease, decreasing in decompensated MMVD. ANIMALS: Thirty-sixclient-owned dogs with MMVD not receiving oral cardiovascular medications. METHODS: Prospective clinical study. Dogs were categorized according to disease severity as ACVIM Stage B1, B2, or C. Seven echocardiographic indices of RV systolic function were measured. Groups were compared by 1-way ANOVA and Tukey's HSD test. Frequencies of cases with cardiac remodeling falling outside previously established reference intervals were compared using Fisher's exact test. Intra- and interobserver measurement variability was calculated for each RV function index. RESULTS: The indices TAPSE (P = 0.029), RV StL (P = 0.012), and RV StRL (P = 0.041) were significantly different between groups. A greater proportion of B2 dogs (7 of 12) had TAPSE values above reference intervals compared with B1 (2 of 12) or C (2 of 12) dogs (P = 0.027). Measurement variability of TAPSE, RV S', and RV StG was clinically acceptable. CONCLUSIONS AND CLINICAL IMPORTANCE: Right ventricular systolic function differs between stages of MMVD, increasing in stage B2, and declining in stage C. The prognostic importance of RV function indices, particularly TAPSE, might be worth evaluating in dogs with MMVD.


Subject(s)
Dog Diseases/diagnostic imaging , Echocardiography/veterinary , Mitral Valve Prolapse/veterinary , Ventricular Function, Right , Animals , Dog Diseases/pathology , Dogs , Female , Male , Mitral Valve Prolapse/diagnostic imaging , Mitral Valve Prolapse/pathology , Prospective Studies
9.
J Vet Intern Med ; 32(1): 72-85, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29214723

ABSTRACT

BACKGROUND: Changes in clinical variables associated with the administration of pimobendan to dogs with preclinical myxomatous mitral valve disease (MMVD) and cardiomegaly have not been described. OBJECTIVES: To investigate the effect of pimobendan on clinical variables and the relationship between a change in heart size and the time to congestive heart failure (CHF) or cardiac-related death (CRD) in dogs with MMVD and cardiomegaly. To determine whether pimobendan-treated dogs differ from dogs receiving placebo at onset of CHF. ANIMALS: Three hundred and fifty-four dogs with MMVD and cardiomegaly. MATERIALS AND METHODS: Prospective, blinded study with dogs randomized (ratio 1:1) to pimobendan (0.4-0.6 mg/kg/d) or placebo. Clinical, laboratory, and heart-size variables in both groups were measured and compared at different time points (day 35 and onset of CHF) and over the study duration. Relationships between short-term changes in echocardiographic variables and time to CHF or CRD were explored. RESULTS: At day 35, heart size had reduced in the pimobendan group: median change in (Δ) LVIDDN -0.06 (IQR: -0.15 to +0.02), P < 0.0001, and LA:Ao -0.08 (IQR: -0.23 to +0.03), P < 0.0001. Reduction in heart size was associated with increased time to CHF or CRD. Hazard ratio for a 0.1 increase in ΔLVIDDN was 1.26, P = 0.0003. Hazard ratio for a 0.1 increase in ΔLA:Ao was 1.14, P = 0.0002. At onset of CHF, groups were similar. CONCLUSIONS AND CLINICAL IMPORTANCE: Pimobendan treatment reduces heart size. Reduced heart size is associated with improved outcome. At the onset of CHF, dogs treated with pimobendan were indistinguishable from those receiving placebo.


Subject(s)
Cardiotonic Agents/therapeutic use , Mitral Valve Prolapse/drug therapy , Pyridazines/therapeutic use , Animals , Cardiomegaly/drug therapy , Cardiomegaly/veterinary , Dog Diseases/drug therapy , Dogs , Echocardiography/veterinary , Heart Diseases/mortality , Heart Diseases/veterinary , Heart Failure/etiology , Heart Failure/veterinary , Mitral Valve Prolapse/diagnostic imaging , Mitral Valve Prolapse/pathology , Prospective Studies , Quality of Life
10.
J Vet Intern Med ; 31(6): 1611-1621, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28865107

ABSTRACT

BACKGROUND: Severity of pulmonary hypertension (PH) in dogs is related to clinical signs and prognosis. HYPOTHESIS/OBJECTIVES: We hypothesized that Doppler echocardiographic (DE) indices of pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR) are influenced by independent factors that create clinically important variability of DE-based estimates of PH in dogs. ANIMALS: Thirty-eight client owned dogs with naturally acquired degenerative atrioventricular valve disease and tricuspid regurgitation (TR). METHODS: Dogs were prospectively enrolled, and target variables were acquired during 4 echocardiographic study periods (lateral recumbency, standing, lateral recumbency after a 6-minute walk test [6MWT], and lateral recumbency after sedation with butorphanol 0.25 mg/kg IM). Statistical methods included repeated measures ANOVA, mixed model analysis, and Chi-squared test of association. RESULTS: There was a significant increase in peak TR flow velocity (TRFV; P < 0.01) after sedation in 78% of dogs, with TRFV increasing by >0.4 m/s in 42% of dogs, independent of stroke volume. A significant effect of study period on DE-estimated PVR was not found (P = 0.15). There were negligible effects of sonographer, body position, and 6MWT on echocardiographic variables of PH. Clinically relevant cyclic variation of TRFV was found. There was an association between estimation of right atrial pressure based on subjective assessment and estimation based on cranial vena cava collapsibility (P = 0.03). CONCLUSIONS AND CLINICAL IMPORTANCE: The increase in TRFV observed with sedation could change assessment of PH severity and impact prognostication and interpretation of treatment response. Further studies with invasive validation are needed.


Subject(s)
Blood Pressure Determination/veterinary , Dog Diseases/diagnostic imaging , Echocardiography, Doppler/veterinary , Heart Valve Diseases/veterinary , Animals , Butorphanol/administration & dosage , Butorphanol/pharmacology , Dogs , Echocardiography, Doppler/drug effects , Echocardiography, Doppler/methods , Exercise Test/veterinary , Female , Heart Valve Diseases/diagnostic imaging , Hypertension, Pulmonary/veterinary , Hypnotics and Sedatives/administration & dosage , Hypnotics and Sedatives/pharmacology , Male , Posture , Tricuspid Valve Insufficiency , Vascular Resistance
11.
J Vet Intern Med ; 30(6): 1765-1779, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27678080

ABSTRACT

BACKGROUND: Pimobendan is effective in treatment of dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD). Its effect on dogs before the onset of CHF is unknown. HYPOTHESIS/OBJECTIVES: Administration of pimobendan (0.4-0.6 mg/kg/d in divided doses) to dogs with increased heart size secondary to preclinical MMVD, not receiving other cardiovascular medications, will delay the onset of signs of CHF, cardiac-related death, or euthanasia. ANIMALS: 360 client-owned dogs with MMVD with left atrial-to-aortic ratio ≥1.6, normalized left ventricular internal diameter in diastole ≥1.7, and vertebral heart sum >10.5. METHODS: Prospective, randomized, placebo-controlled, blinded, multicenter clinical trial. Primary outcome variable was time to a composite of the onset of CHF, cardiac-related death, or euthanasia. RESULTS: Median time to primary endpoint was 1228 days (95% CI: 856-NA) in the pimobendan group and 766 days (95% CI: 667-875) in the placebo group (P = .0038). Hazard ratio for the pimobendan group was 0.64 (95% CI: 0.47-0.87) compared with the placebo group. The benefit persisted after adjustment for other variables. Adverse events were not different between treatment groups. Dogs in the pimobendan group lived longer (median survival time was 1059 days (95% CI: 952-NA) in the pimobendan group and 902 days (95% CI: 747-1061) in the placebo group) (P = .012). CONCLUSIONS AND CLINICAL IMPORTANCE: Administration of pimobendan to dogs with MMVD and echocardiographic and radiographic evidence of cardiomegaly results in prolongation of preclinical period and is safe and well tolerated. Prolongation of preclinical period by approximately 15 months represents substantial clinical benefit.


Subject(s)
Cardiomegaly/veterinary , Cardiotonic Agents/therapeutic use , Dog Diseases/drug therapy , Mitral Valve Insufficiency/veterinary , Pyridazines/therapeutic use , Animals , Cardiomegaly/drug therapy , Cardiotonic Agents/adverse effects , Dogs , Female , Heart Failure/drug therapy , Heart Failure/mortality , Heart Failure/veterinary , Male , Mitral Valve Insufficiency/drug therapy , Mitral Valve Insufficiency/mortality , Pyridazines/adverse effects
12.
J Small Anim Pract ; 56(9): 537-52, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26331869

ABSTRACT

OBJECTIVES: There is a growing understanding of the complexity of interplay between renal and cardiovascular systems in both health and disease. The medical profession has adopted the term "cardiorenal syndrome" (CRS) to describe the pathophysiological relationship between the kidney and heart in disease. CRS has yet to be formally defined and described by the veterinary profession and its existence and importance in dogs and cats warrant investigation. The CRS Consensus Group, comprising nine veterinary cardiologists and seven nephrologists from Europe and North America, sought to achieve consensus around the definition, pathophysiology, diagnosis and management of dogs and cats with "cardiovascular-renal disorders" (CvRD). To this end, the Delphi formal methodology for defining/building consensus and defining guidelines was utilised. METHODS: Following a literature review, 13 candidate statements regarding CvRD in dogs and cats were tested for consensus, using a modified Delphi method. As a new area of interest, well-designed studies, specific to CRS/CvRD, are lacking, particularly in dogs and cats. Hence, while scientific justification of all the recommendations was sought and used when available, recommendations were largely reliant on theory, expert opinion, small clinical studies and extrapolation from data derived from other species. RESULTS: Of the 13 statements, 11 achieved consensus and 2 did not. The modified Delphi approach worked well to achieve consensus in an objective manner and to develop initial guidelines for CvRD. DISCUSSION: The resultant manuscript describes consensus statements for the definition, classification, diagnosis and management strategies for veterinary patients with CvRD, with an emphasis on the pathological interplay between the two organ systems. By formulating consensus statements regarding CvRD in veterinary medicine, the authors hope to stimulate interest in and advancement of the understanding and management of CvRD in dogs and cats. The use of a formalised method for consensus and guideline development should be considered for other topics in veterinary medicine.


Subject(s)
Cardio-Renal Syndrome/veterinary , Cat Diseases/diagnosis , Cat Diseases/therapy , Dog Diseases/diagnosis , Dog Diseases/therapy , Animals , Cardio-Renal Syndrome/diagnosis , Cardio-Renal Syndrome/epidemiology , Cardio-Renal Syndrome/therapy , Cat Diseases/epidemiology , Cats , Consensus , Delphi Technique , Dog Diseases/epidemiology , Dogs , Practice Guidelines as Topic , Veterinary Medicine
13.
J Vet Intern Med ; 28(3): 838-46, 2014.
Article in English | MEDLINE | ID: mdl-24597596

ABSTRACT

BACKGROUND: Ivabradine is a negative chronotropic drug with minimal effects on central hemodynamics. Its effect on dynamic obstruction of the left ventricular outflow tract (LVOT) in cats with hypertrophic cardiomyopathy (HCM) remains unknown. HYPOTHESIS/OBJECTIVES: Ivabradine reduces dynamic obstruction of the LVOT in cats with HCM. ANIMALS: Twenty-eight client-owned cats with preclinical HCM and dynamic LVOT obstruction. METHODS: Randomized, double-blind, active-control single dose study. Cats received a single dose of either ivabradine (0.3 mg/kg PO) or atenolol (2 mg/kg PO). Heart rate, echocardiographic variables, and systolic blood pressure (SBP) were recorded before and 3 hours after drug administration. Statistical comparisons were made using ANCOVA. RESULTS: Peak velocity in the LVOT was significantly decreased compared to baseline for both drugs; however, the effect was more prominent with atenolol (mean reduction 2.53 m/s; 95% CI 2.07-3.13 m/s) compared to ivabradine (mean reduction 0.32 m/s; 95% CI -0.04 to 0.71 m/s; P < .0001). Echocardiographic indices of systolic function were largely unchanged by ivabradine, but significantly reduced by atenolol. CONCLUSIONS AND CLINICAL IMPORTANCE: A single dose of ivabradine decreases dynamic LVOT obstruction in cats with HCM, but the clinical effect is negligible and inferior compared to that achieved by atenolol.


Subject(s)
Benzazepines/therapeutic use , Cardiomyopathy, Hypertrophic/veterinary , Cardiotonic Agents/therapeutic use , Cat Diseases/drug therapy , Ventricular Dysfunction, Left/veterinary , Adrenergic beta-Antagonists/therapeutic use , Animals , Atenolol/therapeutic use , Cardiomyopathy, Hypertrophic/drug therapy , Cardiomyopathy, Hypertrophic/physiopathology , Cat Diseases/physiopathology , Cats , Double-Blind Method , Echocardiography/veterinary , Female , Ivabradine , Male , Ventricular Dysfunction, Left/drug therapy , Ventricular Dysfunction, Left/physiopathology
14.
J Vet Intern Med ; 28(3): 749-61, 2014.
Article in English | MEDLINE | ID: mdl-24628586

ABSTRACT

Murmurs and arrhythmias are commonly detected in equine athletes. Assessing the relevance of these cardiovascular abnormalities in the performance horse can be challenging. Determining the impact of a cardiovascular disorder on performance, life expectancy, horse and rider or driver safety relative to the owner's future expectations is paramount. A comprehensive assessment of the cardiovascular abnormality detected is essential to determine its severity and achieve these aims. This consensus statement presents a general approach to the assessment of cardiovascular abnormalities, followed by a discussion of the common murmurs and arrhythmias. The description, diagnosis, evaluation, and prognosis are considered for each cardiovascular abnormality. The recommendations presented herein are based on available literature and a consensus of the panelists. While the majority of horses with cardiovascular abnormalities have a useful performance life, periodic reexaminations are indicated for those with clinically relevant cardiovascular disease. Horses with pulmonary hypertension, CHF, or complex ventricular arrhythmias should not be ridden or driven.


Subject(s)
Cardiovascular Abnormalities/veterinary , Horses/abnormalities , Animals , Aortic Valve Insufficiency/veterinary , Arrhythmias, Cardiac/veterinary , Atrial Fibrillation/veterinary , Cardiovascular Abnormalities/therapy , Heart Murmurs/veterinary , Heart Septal Defects, Ventricular/veterinary , Horse Diseases/therapy , Mitral Valve Insufficiency/veterinary , Tricuspid Valve Insufficiency/veterinary
15.
J Vet Intern Med ; 28(2): 277-83, 2014.
Article in English | MEDLINE | ID: mdl-24433302

ABSTRACT

BACKGROUND: The prevalence of systemic hypertension (SHT) in Shetland Sheepdogs has not been reported. HYPOTHESIS/OBJECTIVES: SHT is common in Shetland Sheepdogs and positively correlated with proteinuria. Measurements of forelimb and hindlimb systolic arterial pressure (SAP) are comparable. ANIMALS: Seventy-two clinically healthy, client-owned Shetland Sheepdogs. METHODS: Forelimb and hindlimb SAP were recorded by Doppler ultrasonography. Proteinuria was quantified by urine dipstick, microalbuminuria, and protein:creatinine ratio (UPC). The relationship of UPC, anxiety, age, weight, and heart rate with forelimb SAP was evaluated. RESULTS: The mean forelimb and hindlimb SAP were 132 ± 20 and 118 ± 20 mmHg, respectively. The SAP exceeded 160 mmHg in 9 dogs, suggesting 13% prevalence of SHT. Four dogs had a UPC above 0.5; 2 of these had forelimb SAP exceeding 160 mmHg. Correlation of forelimb and hindlimb SAP was poor (r(2)  = 0.09; P = .011). Bland-Altman plots revealed substantial bias (-14 mmHg) between limb measurements with clinically unacceptable 95% limits of agreement (-60 to 33 mmHg). There was no correlation between forelimb SAP and UPC (P = .06) or anxiety level (P = .49). Age (P < .0001) and heart rate (P = .038) were significant predictors of forelimb SAP; weight (P = .73) was not. CONCLUSIONS: Prevalence of SHT was 13% and not correlated with proteinuria. Forelimb and hindlimb SAP were poorly correlated; therefore, trends in an individual animal should be monitored using the same measurement site. Additionally, values for Doppler SAP were determined in Shetland Sheepdogs.


Subject(s)
Blood Pressure/physiology , Dog Diseases/physiopathology , Forelimb/blood supply , Hindlimb/blood supply , Proteinuria/veterinary , Age Factors , Animals , Blood Pressure Determination/methods , Blood Pressure Determination/veterinary , Dog Diseases/diagnostic imaging , Dogs , Female , Forelimb/diagnostic imaging , Heart Rate/physiology , Hindlimb/diagnostic imaging , Hypertension/physiopathology , Hypertension/veterinary , Male , Proteinuria/physiopathology , Ultrasonography, Doppler/methods , Ultrasonography, Doppler/veterinary
16.
Schweiz Arch Tierheilkd ; 155(2): 143-7, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23385073

ABSTRACT

In this article the myocardial expression of different hyperpolarization-activated, cyclic nucleotide-gated (HCN) isoforms in myocardial tissue from healthy control cats and cats with hypertrophic cardiomyopathy (HCM) was evaluated. Myocardial tissue samples of the left ventricle of control cats (n = 12) and cats with HCM (n = 4) were collected. Expression of feline HCN was determined by immunoblot analysis using antibodies against HCN2 and HCN4. Optical densities of HCN bands were compared among groups by use of the Mann-Whitney Rank Sum test. HCN4 was reliably detected in myocardial tissue whereas HCN2 was not. HCN4 expression was significantly increased in left ventricular (LV) myocardial samples of cats with HCM (P = 0.036) compared to control cats. Results indicate that myocardial HCN4 expression can be evaluated in cats by immunoblot analysis and that HCN4 expression is upregulated in LV myocardial tissue of cats with HCM. The pathophysiological importance of HCN overexpression with regard to myocyte function and altered automaticity deserves further study.


Subject(s)
Cardiomyopathy, Hypertrophic/veterinary , Cat Diseases/metabolism , Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels/metabolism , Myocardium/metabolism , Animals , Antibodies/immunology , Antibody Specificity , Blotting, Western/veterinary , Cardiomyopathy, Hypertrophic/metabolism , Case-Control Studies , Cats , Heart Ventricles , Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels/immunology
17.
J Vet Intern Med ; 25(5): 1010-6, 2011.
Article in English | MEDLINE | ID: mdl-21985136

ABSTRACT

BACKGROUND: B-type natriuretic peptide concentrations reliably distinguish between cardiac and respiratory causes of dyspnea, but its utility to detect asymptomatic cats with occult cardiomyopathy (OCM) is unresolved. HYPOTHESIS/OBJECTIVES: Determine whether plasma N terminal probrain natriuretic peptide (NT-proBNP) concentration can discriminate asymptomatic cats with OCM from normal cats, and whether NT-proBNP concentration correlates with clinical, biochemical, and echocardiographic parameters. ANIMALS: One hundred and fourteen normal, healthy cats; 113 OCM cats. METHODS: Prospective, multicenter, case-controlled study. NT-proBNP was prospectively measured and cardiac status was determined from history, physical examination, and M-mode/2D/Doppler echocardiography. Optimal cut-off values were derived using receiver operating characteristic (ROC) curve analysis. RESULTS: NT-proBNP was higher (median, interquartile range [25th and 75th percentiles]) in (1) OCM (186 pmol/L; 79, 478 pmol/L) versus normal (24 pmol/L; 24, 32 pmol/L) (P < .001); and (2) hypertrophic obstructive cardiomyopathy (396 pmol/L; 205, 685 pmol/L) versus hypertrophic cardiomyopathy (112 pmol/L; 48, 318 pmol/L) (P < .001). In OCM, NT-proBNP correlated (1) positively with LVPWd (ρ = 0.23; P = .01), LA/Ao ratio (ρ = 0.31; P < .001), LVs (ρ = 0.33; P < .001), and troponin-I (ρ = 0.64; P < .001), and (2) negatively with %FS (ρ = -0.27; P = .004). Area under ROC curve was 0.92; >46 pmol/L cut-off distinguished normal from OCM (91.2% specificity, 85.8% sensitivity); >99 pmol/L cut-off was 100% specific, 70.8% sensitive. CONCLUSIONS AND CLINICAL IMPORTANCE: Plasma NT-proBNP concentration reliably discriminated normal from OCM cats, and was associated with several echocardiographic markers of disease severity. Further studies are needed to assess test performance in unselected, general feline populations, and evaluate relationships between NT-proBNP concentrations and disease progression.


Subject(s)
Cardiomyopathies/veterinary , Cat Diseases/diagnosis , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Animals , Biomarkers/blood , Cardiomyopathies/blood , Cardiomyopathies/diagnosis , Case-Control Studies , Cat Diseases/blood , Cats , Female , Male , Sensitivity and Specificity
18.
J Vet Intern Med ; 25(3): 469-76, 2011.
Article in English | MEDLINE | ID: mdl-21418320

ABSTRACT

BACKGROUND: Ivabradine is a novel negative chronotropic drug used for treatment of ischemic heart disease in people. Little is known about its effects and safety in cats. HYPOTHESIS/OBJECTIVES: Ivabradine is not inferior to atenolol with regard to clinical tolerance, heart rate (HR) reduction, and effects on cardiac function in healthy, lightly sedated cats. ANIMALS: Ten healthy laboratory cats. METHODS: Physical examination, systolic blood pressure measurement, and transthoracic echocardiography were performed in all cats at baseline and after oral administration (4 weeks each) of ivabradine (0.3 mg/kg q12h) and atenolol (6.25 mg/cat q12h; 1.0-1.7 mg/kg) in a prospective, double-blind, randomized, active-control, fully crossed study. A priori noninferiority margins for the effects of ivabradine compared with atenolol were set at 50% (f = 0.5) based on predicted clinical relevance, observer measurement variability, and in agreement with FDA guidelines. Variables were compared by use of 2-way repeated measures ANOVA. RESULTS: Ivabradine was clinically well tolerated with no adverse events observed. HR (ivabradine, P < .001; atenolol, P < .001; ivabradine versus atenolol, P = .721) and rate-pressure product (RPP) (ivabradine, P < .001; atenolol, P = .001; ivabradine versus atenolol, P = .847) were not different between treatments. At the dosages used, ivabradine demonstrated more favorable effects than atenolol on echocardiographic indices of left ventricular (LV) systolic and diastolic function and left atrial performance. CONCLUSIONS AND CLINICAL IMPORTANCE: Ivabradine is not inferior to atenolol with regard to effects on HR, RPP, LV function, left atrial performance, and clinical tolerance. Clinical studies in cats with hypertrophic cardiomyopathy are needed to validate these findings.


Subject(s)
Atenolol/pharmacology , Benzazepines/pharmacology , Cats/physiology , Heart Rate/drug effects , Ventricular Function, Left/drug effects , Animals , Anti-Arrhythmia Agents/pharmacology , Blood Pressure/drug effects , Cardiotonic Agents/pharmacology , Cross-Over Studies , Double-Blind Method , Female , Ivabradine
20.
J Vet Intern Med ; 24(6): 1358-68, 2010.
Article in English | MEDLINE | ID: mdl-20840304

ABSTRACT

BACKGROUND: Echocardiographic prediction of congestive heart failure (CHF) in dogs has not been prospectively evaluated. HYPOTHESIS: CHF can be predicted by Doppler echocardiographic (DE) variables of left ventricular (LV) filling in dogs with degenerative mitral valve disease (MVD) and dilated cardiomyopathy (DCM). ANIMALS: Sixty-three client-owned dogs. METHODS: Prospective clinical cohort study. Physical examination, thoracic radiography, analysis of natriuretic peptides, and transthoracic echocardiography were performed. Diagnosis of CHF was based upon clinical and radiographic findings. Presence or absence of CHF was predicted using receiver-operating characteristic (ROC) curve, multivariate logistic and stepwise regression, and best subsets analyses. RESULTS: Presence of CHF secondary to MVD or DCM could best be predicted by E:isovolumic relaxation time (IVRT) (area under the ROC curve [AUC]=0.97, P<.001), respiration rate (AUC=0.94, P<.001), Diastolic Functional Class (AUC=0.93, P<.001), and a combination of Diastolic Functional Class, IVRT, and respiration rate (R2=0.80, P<.001) or Diastolic Functional Class (AUC=1.00, P<.001), respiration rate (AUC=1.00, P<.001), and E:IVRT (AUC=0.99, P<.001), and a combination of Diastolic Functional Class and E:IVRT (R2=0.94, P<.001), respectively, whereas other variables including N-terminal pro-brain natriuretic peptide, E:Ea, and E:Vp were less useful. CONCLUSION AND CLINICAL IMPORTANCE: Various DE variables can be used to predict CHF in dogs with MVD and DCM. Determination of the clinical benefit of such variables in initiating, modulating, and assessing success of treatments for CHF needs further study.


Subject(s)
Dog Diseases/diagnostic imaging , Echocardiography, Doppler/veterinary , Heart Failure/veterinary , Animals , Diastole , Dog Diseases/blood , Dogs , Female , Heart Failure/blood , Heart Failure/diagnostic imaging , Male , Mitral Valve/physiology , Natriuretic Peptides/blood , Respiratory Rate
SELECTION OF CITATIONS
SEARCH DETAIL
...